At the pre-weaning period, the SCB treatment significantly (p < 0.05) influenced 6 pathways (cell cycle, EGFR tyrosine kinase inhibitor resistance, bile secretion, Fanconi anemia pathway, mRNA surveillance pathway and oxytocin signaling pathway) in IlM and 5 pathways (caffeine metabolism, cAMP signaling pathway, steroid biosynthesis, proteasome and dopaminergic synapse) in RuD but had no impact on other GIT sites (Table 7) compared to CTL treatment. This evidence concerns the gene OXT and Fanconi anemia.